Walgreens, Prothena partner to boost enrollment for Alzheimer’s disease clinical trial
Click Here to Manage Email Alerts
Walgreens and Prothena have announced a partnership to expand patient identification and recruitment for Prothena’s ongoing study of PRX012, an investigational anti-amyloid beta antibody for the treatment of Alzheimer’s disease.
According to a joint release, Walgreens will engage its national network of health care companies and compliance infrastructure to identify patient populations and increase awareness for the ASCENT-2 clinical trial for PRX012, which has been granted fast track designation by the FDA.
With nearly 9,000 locations nationwide, many of which are in underserved areas, Walgreens can aid recruitment of potentially eligible patients and their caregivers in the pharmacy or at home by informing them about the trial and inviting interested individuals to prescreen at one of Prothena’s clinical trial sites, the companies stated.
This effort aligns with the Equity in Neuroscience and Alzheimer’s Clinical Trials Act, which aims to increase participation of underrepresented populations in Alzheimer’s and dementia-related clinical trials.
“Alzheimer’s disease is an incredibly complex disorder and requires all stakeholders to work together to develop and evaluate effective therapies,” Ramita Tandon, Walgreen’s chief clinical trials officer, said in the release. “Our aim is to help build a more representative patient population for Alzheimer’s research, particularly among underserved and diverse communities, to create a better understanding of this disease.”
Prothena’s ongoing phase 1 PRX012 single ascending dose and multiple ascending dose studies are expected to release topline data by the end of 2023, per the release.
“This innovative partnership will allow Prothena to leverage Walgreens unique capabilities to engage a broader and more representative patient population for potential enrollment in ASCENT-2 and accelerate the development of the PRX012 program to bring this potential best-in-class anti-amyloid beta antibody to patients as soon as possible,” Hideki Garren, MD, PhD, chief medical officer at Prothena, told Healio in an email.